# Congressional stock trades in CRNX (Crinetics Pharmaceuticals, Inc.)

Congressional stock trades in Crinetics Pharmaceuticals, Inc. (CRNX) from House and Senate STOCK Act filings. See which members of Congress bought or sold, disclosed amounts, and filing dates.

- Industry: Pharmaceutical Preparations
- Last close: $84.95
- Price updated: Sep 9, 2026
- Total congressional trades: 4
- Politicians trading: 2
- Last traded: Jul 30, 2026
- Source: https://tryglasshouse.ai/companies/CRNX.md

## Trading History

- Page: 1 of 1
- Results: 4 of 4
- Pagination query parameter: `page`

## 1. Gilbert Ray Cisneros, Jr.

- Member: Democrat, House
- Transaction: Sell, $15,001 - $50,000
- Dates: traded Jul 30, 2026, disclosed Sep 4, 2026
- Market context: - at trade, $84.95 current (-)
- Politician: https://tryglasshouse.ai/politicians/C001123.md
- Record: https://tryglasshouse.ai/trades/68d19835-5f4d-4270-8e3b-2902bf45a574.md

## 2. Gilbert Ray Cisneros, Jr.

- Member: Democrat, House
- Transaction: Buy, $1,001 - $15,000
- Dates: traded Apr 17, 2025, disclosed May 6, 2025
- Market context: $30.42 at trade, $84.95 current (+179.26%)
- Politician: https://tryglasshouse.ai/politicians/C001123.md
- Record: https://tryglasshouse.ai/trades/222501a9-9d2c-4aec-8526-36773a3fd72e.md

## 3. Josh Gottheimer

- Member: Democrat, House
- Transaction: Sell, $1,001 - $15,000
- Dates: traded Mar 19, 2025, disclosed Apr 10, 2025
- Market context: $34.67 at trade, $84.95 current (+145.02%)
- Politician: https://tryglasshouse.ai/politicians/G000583.md
- Record: https://tryglasshouse.ai/trades/c2582242-5320-4a2f-8c13-094bc5cea66a.md

## 4. Gilbert Ray Cisneros, Jr.

- Member: Democrat, House
- Transaction: Buy, $1,001 - $15,000
- Dates: traded Jan 29, 2025, disclosed Feb 11, 2025
- Market context: $39.38 at trade, $84.95 current (+115.72%)
- Politician: https://tryglasshouse.ai/politicians/C001123.md
- Record: https://tryglasshouse.ai/trades/ce70d37c-ab48-47ff-8ec7-80d42253b99d.md



## About Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

Prices and percentage changes are market context, not portfolio returns. This information is not financial advice.